WASHINGTON—A panel of cancer experts has voted against a new use for Amgen's Xgeva in prostate cancer, saying the drug's ability to slow the spread of the disease did not translate into meaningful benefits for patients The Food and Drug Administration's cancer drug panel voted 12-1 that the benefits of the drug did not outweigh its
Full Story